A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
Clinical trial NCT04526899 · COMPLETED
Trial details
- NCT number
- NCT04526899
- Sponsor
- BioNTech SE
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-19
- Primary completion
- 2024-01-25
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.